Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 75 descriptions
| No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 5009111000001105 | - | - | - | - | [1] 43 43 💬1. 5009111000001105
| ||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | ALEMTUZUMAB | [1] Alemtuzumab Alemtuzumab | [1] Alemtuzumab
Alemtuzumab
💬2. ALEMTUZUMAB
| [1] CD52 CD52 💬2. ALEMTUZUMAB
| - | [17] 13 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 💬2. ALEMTUZUMAB
| ||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | Avacopan | [1] Avacopan Avacopan | [1] Avacopan
Avacopan
💬3. Avacopan
| [1] C5AR1 C5AR1 💬3. Avacopan
| [6] Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Staphylococcus aureus infection 💬 [6] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Ne ... | [3] 43 43, 44, 222 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||
| 4 | Azathioprine | [1] Azathioprine Azathioprine | [1] Azathioprine
Azathioprine
💬4. Azathioprine
| - | - | [21] 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 💬4. Azathioprine
| ||||||||||||||||||||||||||||||||||||||||||||||||
| 5 | BELIMUMAB | [1] Belimumab Belimumab | [1] Belimumab
Belimumab
💬5. BELIMUMAB
| [1] TNFSF13B TNFSF13B 💬5. BELIMUMAB
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 [4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B ... | [13] 11 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 💬5. BELIMUMAB
| ||||||||||||||||||||||||||||||||||||||||||||||||
| 6 | Belimumab 10 mg/kg | [1] Belimumab Belimumab | [1] Belimumab
Belimumab
💬6. Belimumab 10 mg/kg
| [1] TNFSF13B TNFSF13B 💬6. Belimumab 10 mg/kg
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 [4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B ... | [3] 43 43, 46, 49 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||
| 7 | Benlysta | [1] Belimumab Belimumab | [1] Belimumab
Belimumab
💬7. Benlysta
| [1] TNFSF13B TNFSF13B 💬7. Benlysta
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 [4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B ... | [5] 43 43, 49, 53, 66, 222 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||
| 8 | Benlysta 400 mg powder for concentrate for solution for infusion | [1] Belimumab Belimumab | [1] Belimumab
Belimumab
💬8. Benlysta 400 mg powder for concentrate for solution for infusion
| [1] TNFSF13B TNFSF13B 💬8. Benlysta 400 mg powder for concentrate for solution for infusion
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 [4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B ... | [2] 43 43, 49 💬
| ||||||||||||||||||||||||||||||||||||||||||||||||
| 9 | Benlysta 400mg polvere per concentrato per soluzione per infusione | [1] Belimumab Belimumab | [1] Belimumab
Belimumab
💬9. Benlysta 400mg polvere per concentrato per soluzione per infusione
| [1] TNFSF13B TNFSF13B 💬9. Benlysta 400mg polvere per concentrato per soluzione per infusione
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 [4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B ... | [1] 43 43 💬9. Benlysta 400mg polvere per concentrato per soluzione per infusione
| ||||||||||||||||||||||||||||||||||||||||||||||||
| 10 | Blisibimod | [1] Blisibimod Blisibimod | [1] Blisibimod
Blisibimod
💬10. Blisibimod
| - | - | [5] 43 43, 44, 49, 63, 66 💬
|